Fraud by Boston University researcher
The Scientist reported:
Sheng Wang, assistant professor of medicine at the Boston University School of Medicine (BUSM) Cancer Research Center until last month, committed research misconduct, the Department of Health and Human Services’ Office of Research Integrity (ORI) announced last Friday (August 5). Specifically, the ORI determined that Wang fabricated data published in two 2009 papers in the journals Molecular Endocrinology (ME) and Oncogene, both of which Wang has agreed to retract.
The technical area:
HIC1 (“hypermethylated in cancer 1”) is a protein known to suppress cell growth. The gene that encodes HIC1 was recently shown to be epigenetically disrupted in human tumors, and its expression has been linked to better outcomes in some breast cancers.
There are patent applications in this general technical area. For example,
US 20110190161, titled Methylation Profile of Cancer
US 20110171642, titled Analysing Methylation Specific PCR by Amplicon Melting
Sheng Wang, assistant professor of medicine at the Boston University School of Medicine (BUSM) Cancer Research Center until last month, committed research misconduct, the Department of Health and Human Services’ Office of Research Integrity (ORI) announced last Friday (August 5). Specifically, the ORI determined that Wang fabricated data published in two 2009 papers in the journals Molecular Endocrinology (ME) and Oncogene, both of which Wang has agreed to retract.
The technical area:
HIC1 (“hypermethylated in cancer 1”) is a protein known to suppress cell growth. The gene that encodes HIC1 was recently shown to be epigenetically disrupted in human tumors, and its expression has been linked to better outcomes in some breast cancers.
There are patent applications in this general technical area. For example,
US 20110190161, titled Methylation Profile of Cancer
US 20110171642, titled Analysing Methylation Specific PCR by Amplicon Melting
posted by Lawrence B. Ebert at 3:59 PM
0 Comments:
Post a Comment
<< Home